Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00716001 |
Recruitment Status : Unknown
Verified July 2008 by Osaka General Medical Center.
Recruitment status was: Not yet recruiting
First Posted : July 15, 2008
Last Update Posted : July 15, 2008
|
Sponsor:
Osaka General Medical Center
Information provided by:
Osaka General Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is to evaluate the efficacy of sodium bicarbonate plus N-acetylcysteine for the prevention of contrast-induced nephropathy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Renal Failure | Drug: N-acetylcysteine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Study Start Date : | July 2008 |
Estimated Primary Completion Date : | June 2009 |
Resource links provided by the National Library of Medicine

MedlinePlus related topics:
Kidney Failure
Drug Information available for:
Acetylcysteine
Arm | Intervention/treatment |
---|---|
Active Comparator: NAC |
Drug: N-acetylcysteine |
Placebo Comparator: nonNAC |
Drug: N-acetylcysteine |
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients with chronic renal failure(serum creatinine >1.1mg/dl) undergoing elective percutaneous coronary intervention
Exclusion Criteria:
- administered with sodium bicarbonate and/or N-acetylcysteine and/or contrast media within 72 hours.
- pregnancy
- congestive heart failure
- allergy to sodium bicarbonate and/or N-acetylcysteine
- hemodialysis
No Contacts or Locations Provided
Responsible Party: | Masaharu Masuda, Osaka General Medical Center |
ClinicalTrials.gov Identifier: | NCT00716001 |
Other Study ID Numbers: |
OPTSB |
First Posted: | July 15, 2008 Key Record Dates |
Last Update Posted: | July 15, 2008 |
Last Verified: | July 2008 |
Keywords provided by Osaka General Medical Center:
patients with chronic renal failure undergoing elective percutaneous coronary intervention |
Additional relevant MeSH terms:
Renal Insufficiency Kidney Failure, Chronic Kidney Diseases Urologic Diseases Renal Insufficiency, Chronic Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents |
Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |